Traumatic brain injury (TBI) affects millions of people worldwide every year and current estimates from the World Health Organization suggest that TBI will be the third leading cause of death and disability by the year 2020. Moreover, TBI is believed to significantly increase one's risk of developing other neurological disorders including chronic traumatic encephalopathy (CTE), Alzheimer’s disease (AD), anxiety, depression, and amyotrophic lateral sclerosis (ALS) later in life.  Despite being a prevalent and pressing global medical issue, our understanding of TBI pathoetiology remains incomplete.  Our recent findings provide new insights into both the causes and consequences of meningeal lymphatic dysfunction in TBI and suggest that therapeutics targeting the meningeal lymphatic system may offer strategies to treat TBI.